Eugene Braunwald JCHF 2013;1:1-20

Slides:



Advertisements
Similar presentations
HEART FAILURE (HF) Heart failure is the pathophysiological state in which an abnormality of cardiac function is responsible for failure of the heart to.
Advertisements

Cardiac Drugs in Heart Failure Patients Zoulikha Zair 28 th May 2013 N.B. some drugs overlap with treatment of hypertension….bonus revision wise!!!!
Drugs Used In the Treatment of Congestive Heart Failure(Cont) Garrett J. Gross, Ph.D. Drugs Used In the Treatment of Congestive Heart Failure(Cont) Garrett.
Pharmacologic Treatment of Chronic Systolic Heart Failure John N. Hamaty D.O. FACC, FACOI.
Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.
Medical Progress: Heart Failure. Primary Targets of Treatment in Heart Failure. Treatment options for patients with heart failure affect the pathophysiological.
Renin-Angiotensin-Aldosterone System Juxtaglomerular apparatus secretes renin. Juxtaglomerular apparatus secretes renin. Renin acts on angiotensinogen.
1 Drug Therapy of heart failure. Prof. Azza El-Medani Prof. Abdulrahman Almotrefi.
kvs1ed.ppt 1 Heart and Circulatory Failure Lectures from Pathological Physiology Dental Medicine Study materials from Pathological Physiology,
Pharmacology of Heart failure
Vasoactive peptides By S.Bohlooli, PhD. Vasoactive peptides Vasoconstrictors: Angiotensin II Vasopressin Endothelins Neuropeptide Y urotensin Vasodilators:
Bipyridines :(Amrinone,Milrinone ) only available in parenteral form. Half-life 3-6hrs. Excreted in urine.
Source: Your Guide To Lowering Blood Pressure, Pathophysiology BMS 243 Hypertension Dr. Aya M. Serry 2015/2016.
Heart failure Laszlo L. Tornoci Inst. Pathophysiology Semmelweis University.
Basic Science Series: Pathophysiology of Heart Failure October 27/2009.
PHARMACOLOGIC THERAPY  Standard First-Line Therapies Angiotensin-Converting Enzyme Inhibitors (ACEI) β Blockers Diuretics Digoxin  Second line Therapies.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cirrhotic Cardiomyopathy J Am Coll Cardiol. 2010;56(7):
Date of download: 6/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Quality of Care of and Outcomes for African Americans.
Blood Pressure.
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Angiotensin II type 1 receptor antagonist decreases.
Fig ACCF/AHA Guideline for the management of heart failure
Heart and Circulatory Failure
Drugs for Hypertension
Defibrillator in Acute Myocardial Infarction Trial
AT1 receptor blockade can result in the stimulation of the AT2 receptor. Figure 6. AT1 receptor blockade can result in the stimulation of the.
Heart Failure - Summary
Left Ventricular Dysfunction With Pulmonary Hypertension
by Gregg C. Fonarow, Clyde W. Yancy, Nancy M. Albert, Anne B
A Guide for the Perplexed
Current and future paradigm for prognostication and testing of therapeutics in patients with heart failure using machine learning. Current and future paradigm.
Section III: Neurohormonal strategies in heart failure
The pathophysiology of myocardial infarction-induced heart failure
Hypertension: A Risk Factor For Stroke
Clyde W. Yancy et al. JACC 2017;70:
Sumeska Thavarajah, MD, Daphne H. Knicely, MD, Michael J. Choi, MD 
Improving Transitions in CKD: Failure Mode
Viper venom for diabetic nephropathy
Frederic Rahbari-Oskoui, MD, MS  American Journal of Kidney Diseases 
Step Care Therapy for Hypertension in Diabetic Patients
Deborah J. Clegg, PhD, Michael Cody, MD, Biff F. Palmer, MD 
Antoni Bayés-Genís JCHF 2015;3:
Orly Vardeny et al. JCHF 2014;2:
Viper venom for diabetic nephropathy
Nariman Sepehrvand, and Justin A. Ezekowitz JCHF 2016;4:
Exercise-Based Cardiac Rehabilitation and Improvements in Cardiorespiratory Fitness: Implications Regarding Patient Benefit  Barry A. Franklin, PhD  Mayo.
Drugs Acting on the Renin-Angiotensin-Aldosterone System
John E. Sanderson JCHF 2014;2:93-94
Fig. 2. Evidence-based medication prescriptions
Nat. Rev. Cardiol. doi: /nrcardio
Effect of β-adrenergic Blockers on the Arterial Blood Pressure
Drugs Acting on the Heart
Schematic diagram showing as yet unexplored pathophysiological mechanisms in pulmonary arterial hypertension (PAH). Schematic diagram showing as yet unexplored.
Shannon M. Dunlay, MD, MS, Naveen L. Pereira, MD, Sudhir S
Peter E. Carson et al. JCHF 2015;3:
Maria R. Costanzo et al. JCHF 2016;4:
Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.
Unloading of high-pressure baroceptors (blue circles) in the left ventricle, carotid sinus, and aortic arch generates afferent signals (black) that stimulate.
Rami Doukky et al. JCHF 2016;4:24-35
Adjunctive Therapies in the Treatment of Acute Coronary Syndromes
Comparative Superiority of ACE Inhibitors Over Angiotensin Receptor Blockers for People With CKD: Does It Matter?  Dimitris Mavridis, PhD  American Journal.
Eugene Braunwald JCHF 2013;1:1-20
Svend A. Mortensen et al. JCHF 2014;2:
Fig. 11. Role of endothelial dysfunction in the progression of chronic cardiac failure. The diagram depicts the four major underlying and mutually interacting.
Thomas Münzel et al. JACC 2017;70:
Paul A. Gurbel, and Udaya S. Tantry JCHF 2014;2:1-14
Schematic of the interaction between the renin-angiotensin-aldosterone system (RAAS) system and the natriuretic peptides and how the RAAS modulators and.
β-Blocker Use for the Stages of Heart Failure
Sumeska Thavarajah, MD, Daphne H. Knicely, MD, Michael J. Choi, MD 
Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy  Andrea M. Steely, MD, Peter W.
Presentation transcript:

Eugene Braunwald JCHF 2013;1:1-20 Interplay Between Cardiac Function and Neurohumoral and Cytokine Systems Myocardial injury, which may have any of a number of causes, might depress cardiac function, which in turn may cause activation of the sympathoadrenal system and the renin-angiotensin-aldosterone system and the elaboration of endothelin, arginine vasopressin, and cytokines such as tumor necrosis factor (TNF)-α. In acute heart failure (left), these are adaptive and tend to maintain arterial pressure and cardiac function. In chronic heart failure (right), they cause maladaptive hypertrophic remodeling and apoptosis, which cause further myocardial injury and impairment of cardiac function. The horizontal line on the right shows that chronic maladaptive influences can be inhibited by angiotensin-converting enzyme inhibitors, β-adrenergic blockers, angiotensin II type 1 receptor blockers, and/or aldosterone antagonists. Eugene Braunwald JCHF 2013;1:1-20 American College of Cardiology Foundation